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Abstract 
 
 Increasing lines of evidence show that resveratrol, a polyphenol compound contained in 
several dietary products, exhibits cytoprotective actions.  Notably, resveratrol activates 
sirtuin family of NAD-dependent histone deacetylases implicated in regulation of various 
cellular processes including gene transcription, DNA repair and apoptosis.  Here we 
examined neuroprotective effect of resveratrol on dopaminergic neurons in organotypic 
midbrain slice culture.  Resveratrol and quercetin, another sirtuin-activating polyphenol, 
prevented the decrease of dopaminergic neurons and the increase of propidium iodide uptake 
into slices induced by a dopaminergic neurotoxin 1-methyl-4-phenyl pyridinium (MPP+).  
Resveratrol also provided concentration-dependent neuroprotective effects against sodium 
azide, a mitochondrial complex IV inhibitor, and thrombin (EC number 3.4.21.5), a 
microglia-activating agent.  Sirtuin inhibitors such as nicotinamide and sirtinol did not 
attenuate the protective effect of resveratrol against MPP+ cytotoxicity.  Instead, we found 
that resveratrol prevented accumulation of reactive oxygen species, depletion of cellular 
glutathione, and cellular oxidative damage induced by MPP+, suggesting involvement of 
antioxidative properties in the neuroprotective action of resveratrol.  On the other hand, 
resveratrol as well as a sirtuin activator NAD inhibited dopaminergic neurotoxicity of a DNA 
alkylating agent, N-methyl-N’-nitro-N-nitrosoguanidine (MNNG).  Moreover, 
MNNG-induced increase in acetylation of p53, a representative target of sirtuin deacetylase 
activity, was suppressed by resveratrol.  These results indicate that resveratrol can exert 
neuroprotective actions in dopaminergic neurons.  Either antioxidative activity or 
sirtuin-activating potential may play an important role in the neuroprotectice actions of 
resveratrol against different kinds of insults. 
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1. Introduction 
 
 Selective and progressive degeneration of dopaminergic neurons in the substantia nigra 
pars compacta is a pathological feature of Parkinson’s disease (PD).  Accumulating evidence 
indicates that multiple factors, including genetic and environmental ones, contribute to 
acceleration of dopaminergic neurodegeneration in this neurological disorder [1].  
Particularly, mitochondrial dysfunction has been considered one of the most important factors 
involved in the pathogenesis of PD [2].  This notion is supported by the finding that 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), after metabolic conversion to 
1-methyl-4-phenyl pyridinium (MPP+), interferes with mitochondrial respiration via inhibition 
of complex I, thereby triggering dopaminergic neurodegeneration that leads to parkinsonism 
[3].  Activities of mitochondrial complexes I and IV are reduced in PD patients [4].  
Remarkably, several genetic factors recently implicated in familial forms of PD, such as DJ-1 
and PINK1, may have relevance to mitochondrial function [2]. 
 
 Besides mechanisms intrinsic to dopaminergic neurons, cell-to-cell interactions associated 
with inflammatory reactions may also play an important role in PD pathogenesis [5].  A 
large number of reactive microglia are found in the substantia nigra of PD brain [6], and 
experimentally, microglial activation by lipopolysaccharide or by thrombin leads to 
degeneration of midbrain dopaminergic neurons in vitro [7,8] and in vivo [9].  Overall, 
strategies to protect dopaminergic neurons from progressive degeneration should have 
potentials to counteract multiple kinds of insults. 
 
 Resveratrol is a naturally occurring polyphenol contained in red wine and other dietary 
products.  Since the discovery of chemopreventive activity against skin cancer [10], 
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resveratrol has been shown to exhibit a wide range of biological actions including 
anticarcinogenesis, cardiovascular protection and anti-inflammatory effects.  Cellular and 
molecular bases of these actions remain unresolved, but may involve regulation of the 
activities and expression levels of enzymes and proteins, regulation of ion channels, as well as 
antioxidative actions [11].  Importantly, resveratrol activates Sir2-family proteins (sirtuins) 
categorized into class III histone deacetylases [12].  Sirtuins play pivotal roles in various 
cellular processes, including gene silencing, DNA repair and life span extension in response 
to caloric restriction.  These functions of sirtuins may be based on the fact that they can 
deacetylate and regulate diverse families of transcription factors including p53, FOXO, 
NF-κB and Ku70 [13].  
 
 A growing body of evidence suggests that resveratrol provides beneficial influences on 
neuronal cells [14,15].  For example, resveratrol protects cultured hippocampal neurons from 
cytotoxicity of nitric oxide (NO) and β-amyloid [16,17], striatal neurons from polyglutamine 
toxicity [18] and dorsal root ganglion neurons from axon degeneration [19].  
Neuroprotective effect of resveratrol in vivo has also been reported for damage induced by 
kainate [20] and global ischemia [21].  On the other hand, no information is available 
concerning dopaminergic neurons, although one study demonstrated protective effect of 
resveratrol against MPP+ toxicity in PC12 cells [22].  Here we investigated neuroprotective 
potential of resveratrol against several kinds of neurotoxic insults on dopaminergic neurons 
maintained in midbrain slice culture. 
 
 
2. Materials and Methods 
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2.1. Drugs and chemicals 
 
 Unless otherwise indicated, drugs and chemicals were obtained from Nacalai Tesque 
(Kyoto, Japan).  MPP+, resveratrol, quercetin, thrombin, nicotinamide, sirtinol and NAD 
were obtained from Sigma-Aldrich Chemicals (St Louis, MO, USA).  
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) was obtained form Wako Pure Chemicals 
(Osaka, Japan). 
 
2.2. Culture preparation and drug treatment 
 
 Organotypic midbrain slice cultures were prepared according to the methods described 
previously [7,8].  Briefly, postnatal 2-3 day-old Wistar rats (Nihon SLC, Shizuoka, Japan) 
were anesthetized by hypothermia and were decapitated, the brain was removed from the 
skull and separated into two hemispheres.  Coronal midbrain slices (350 μm thick) were 
prepared under sterile conditions, and transferred onto microporous membranes (six slices per 
each membrane; MillicellR-CM, Millipore, Bedford, MA, USA) in 6-well plates.  Culture 
medium, consisting of 50% minimal essential medium/HEPES, 25% Hanks’ balanced salt 
solution and 25% heat-inactivated horse serum (Invitrogen Japan, Tokyo, Japan) 
supplemented with 6.5 mg/ml glucose, 2 mM L-glutamine and 10 U/ml penicillin-G / 10 
μg/ml streptomycin (Invitrogen Japan), was supplied at a volume of 0.76 ml per each well.  
Culture medium was exchanged with fresh medium on the next day of slice preparation, and 
thereafter, every two days.  Slices were maintained in a 34 °C, 5% CO2 humidified 
atmosphere. 
 
 At 17-18 days in vitro, slices were exposed to drugs by transfer of culture inserts to 
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culture wells filled with 0.76 ml of drug-containing serum-free medium.  Serum-free 
medium consisted of 75% minimal essential medium/HEPES and 25% Hank’s balanced salt 
solution supplemented with 6.5 mg/ml glucose, 2 mM L-glutamine and 10 U/ml penicillin-G / 
10 μg/ml streptomycin.  
 
2.3. Immunohistochemistry 
 
 After drug treatment, cultures were fixed with 4% paraformaldehyde and processed for 
tyrosine hydroxylase (TH; EC number 1.14.16.2) immunohistochemistry [7].  We used 
rabbit anti-TH polyclonal antibody (1:500, AB-152, Chemicon International, Temecula, CA, 
USA) as the primary antibody, and biotinylated anti-rabbit IgG from goat (1:200, Vector Lab., 
Burlingame, CA, USA) as the secondary antibody.  After incubation with the secondary 
antibody, cultures were treated with avidin-biotinylated horseradish peroxidase complex 
(Vectastain Elite ABC kit, Vector Lab.), and then peroxidase was visualized with 
diaminobenzidine and H2O2.  The maximal number of TH-positive dopaminergic neurons in 
an area of 520 × 670 μm2 in individual slices was counted. 
 
 Oxidative damage of slice cultures was evaluated by immunohistochemistry for 
8-hydroxyguanine [23].  Procedures were essentially the same as those for TH 
immunohistochemistry except that, prior to application of antibodies, fixed tissues were 
treated with 10 μg/ml proteinase K (EC number 3.4.21.64; Ambion, Austin, TX, USA) for 25 
min.  Anti-8-hydroxyguanine monoclonal antibody (1:500, R&D systems, Minneapolis, MN, 
USA) and biotinylated anti-mouse IgG(H+L) from horse (1:200, Vector Lab.) were used as a 
primary and a secondary antibody, respectively. 
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 Expression of SIRT1 in dopaminergic neurons was determined by double 
immunofluorescence.  Mouse anti-TH (1:1000, Sigma) and rabbit anti-SIRT1(H-300) (1:200, 
Santa Cruz Biotech., Santa Cruz, CA, USA) were used as primary antibodies.  Alexa FluorR 
568 goat anti-mouse IgG(H+L) (1:400, Molecular Probes, Eugene, OR, USA) was used to 
detect TH immunoreactivity.  Tyramide Signal Amplification kit with Alexa FluorR 488 
(Molecular Probes) was used to detect specific labeling of SIRT1 [24]. 
 
2.4. Propidium iodide uptake 
 
 Propidium iodide (PI) uptake was used for assessment of overall injury of slice cultures 
[8].  PI (Wako Pure Chemicals) was applied at 5 μg/ml during drug treatment, and the 
fluorescence in slices was observed through an inverted fluorescence microscope with a 
rhodamine filter set.  Fluorescence images were captured through a monochrome chilled 
CCD camera, and stored images were analyzed with NIH image 1.62 software.  The 
averaged signal intensity in an area of 180 × 180 μm2 was obtained as the fluorescence value 
of each slice.  Fluorescence values were normalized with the intensity of fluorescence in 
cultures that received 300 μM MPP+ for 48 h as 100%. 
 
2.5. Nitrite quantification 
 
 Amount of NO released during thrombin treatment was quantified as the concentration of 
nitrite in culture medium by Griess method.  One hundred μl of culture supernatants was 
collected and reacted with an equal volume of Griess reagent (1% sulfanilamide and 0.1% 
N-(1-naphthyl)-ethylenediamine dihydrochloride in 2.5% phosphoric acid) for 10 min at room 
temperature, and absorbance of diazonium compound was measured at a wavelength of 540 
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nm.  The absolute level of nitrite was determined with reference to a standard curve obtained 
with sodium nitrite. 
 
2.6. Measuremen of intracellular levels of reactive oxygen species 
 
 After drug treatment, slices were washed with Dulbecco’s modified Eagle’s medium 
(Invitrogen) and loaded with 30 μM 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA; 
Molecular Probes) for 30 min at 34 °C.  Images of fluorescence of 2’,7’-dichlorofluorescein 
(DCF), which was produced by oxidation of DCFH within cells, were captured through a 
monochrome chilled CCD camera.  The fluorescence intensity of individual slices was 
determined in the same manner as that in PI fluorescence experiments. 
 
2.7. Glutathione determination 
 
 Glutathione content was measured according to the method described by Elleman [25] 
with modification.  After drug treatment, slices were collected in 10 mM PBS and 
centrifuged at 7000 g at 4 °C for 10 min.  Then the samples were homogenized in 80 μl of 
0.01 M HCl, and 20 μl of 5% 5-sulfosalicylic acid dehydrate was added.  Lysates were 
centrifuged at 15000 g at 4 °C for 30 min.  To 80 μl of this supernatant, 501.1 μl of PBS 
containing 0.5 mM EDTA, 65 μl of 4 mM NADPH and 10 μl of 1 mg/ml glutathione 
reductase (EC number 1.8.1.7) were added and incubated for 15 min at room temperature.  
After addition of 50 μl of 10 mM 5,5’-dithiobis-(2-nitrobenzoate), the absorbance of the 
mixture was measured at a wavelength of 412 nm. 
 
2.8. Western blot analysis 
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  After treatment with MNNG and resveratrol for 72 h, slices were harvested and 
homogenized in ice-cold lysis buffer containing 20 mM Tris-HCl (pH 7.0), 25 mM 
β-glycerophosphate (Sigma), 2 mM EGTA·2Na, 1% Triton X-100, 1 mM vanadate, 1% 
aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride and 2 mM dithiothreitol.  Samples 
were mixed with a sample buffer composed of 124 mM Tris-HCl (pH 6.8), 4% SDS, 10% 
glycerol, 0.02% bromophenol blue and 4% 2-mercaptoethanol.  After boiling for 5 min, 
samples were subjected to 12% SDS-polyacrylamide gel electrophoresis for 70 min, followed 
by transfer to PVDF membrane (Millipore) for 70 min.  Membranes were blocked for at 
least 1 h by 5% nonfat milk at room temperature and subsequently incubated with rabbit 
anti-acetylated p53 (1:1000, Upstate) and anti-β-actin (1:50000, Sigma), overnight at 4 °C.  
After incubation with horseradish peroxidase-conjugated secondary antibodies (Vector Lab.) 
at room temperature for 1 h, bands were detected with enhanced chemiluminescence detection 
system (Amersham Biosciences, Piscataway, NJ, USA) and exposed to Fuji X-ray film. 
 
2.9. Statistical analysis 
 
 Results are expressed as mean ± S.E.M.  Statistical significance was evaluated with 
one-way ANOVA followed by Student-Newman-Keuls test, and probability values less than 
5% were considered significant. 
 
 
3. Results 
 
3.1. Resveratrol protects dopaminergic neurons from injuries induced by MPP+, sodium azide 
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and thrombin 
 
 TH immunohistochemistry identified dopaminergic neurons with developed dendrites 
localized at a confined region in individual cultured midbrain slices (Fig. 1A).  We first 
examined the effect of resveratrol against the cytotoxicity of MPP+, a mitochodrial complex I 
inhibitor and a well-known dopaminergic neurotoxin.  Application of 30 μM MPP+ to slice 
cultures for 48 h induced a significant decrease in the number of viable dopaminergic neurons.  
In addition, dopaminergic neurons surviving after MPP+ treatment exhibited atrophy of 
dendritic processes and shrinkage of cell bodies (Fig. 1B).  We also assessed PI uptake into 
slices as a measure of whole tissue injury.  Because dopaminergic neurons comprise only a 
small subset of midbrain cells in our cultures (less than 3%), levels of PI fluorescence 
essentially reflect the extent of injury in cells other than dopaminergic neurons [8].  A 
marked increase in PI uptake into whole slices was observed after MPP+ treatment (Fig. 1E), 
suggesting that MPP+ induced cell death also in non-dopaminergic cell population. 
 
 Resveratrol co-applied with 30 μM MPP+ protected dopaminergic neurons in a 
concentration-dependent manner (Fig. 1C, D).  The effect was marginal at a concentration of 
10 μM, and a significant effect was observed with 30 and 100 μM resveratrol.  At these 
concentrations, resveratrol also attenuated whole tissue injury as determined by PI uptake (Fig. 
1E).  Protective effect similar to that of resveratrol was observed when quercetin, another 
sirtuin-activating polyphenol, was applied concomitantly with MPP+ (Fig. 1F, G).  At 100 
μM, quercetin tended to show greater protection than resveratrol against whole tissue injury. 
 
 To determine whether resveratrol can afford dopaminergic neuroprotection against other 
cytotoxic insults, we next examined cytotoxicity of sodium azide, a mitochondrial complex 
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IV inhibitor.  Sodium azide applied at 200 μM for 24 h caused a prominent decrease in the 
number of viable dopaminergic neurons and an increase in PI uptake into slices.  Resveratrol 
(30-100 μM) concomitantly applied with sodium azide protected dopaminergic neurons (Fig. 
2A) and reduced whole tissue injury (Fig. 2B) in a concentration-dependent manner. 
 
 We recently reported that thrombin triggered dopaminergic neurodegeneration via 
activation of microglia and resultant NO production [8].  We found here that resveratrol was 
also effective against thrombin cytotoxicity.  As expected, thrombin applied to slice cultures 
at 300 U/ml for 72 h caused a significant decrease in the number of dopaminergic neurons, an 
increase in PI uptake into slices, and an increase in NO production as reflected by nitrite 
levels in the medium.  Concurrent application of resveratrol (30-100 μM) significantly 
inhibited thrombin-induced loss of dopaminergic neurons (Fig. 2C).  PI uptake into slices 
(Fig. 2D) and nitrite accumulation in the medium (Fig. 2E) were significantly attenuated by 
100 μM resveratrol.  Taken together, these results indicate that resveratrol shows 
neuroprotective effects on dopaminergic neurons undergoing several different kinds of 
insults. 
 
3.2. Protective effect of resveratrol against MPP+ cytotoxicity involves antioxidative actions 
rather than sirtuin-activating properties 
 
 Resveratrol and quercetin have the ability of activating sirtuin family of histone 
deacetylases.  If the protective effects of resveratrol and quercetin on MPP+-induced injury 
are mediated by sirtuins, these effects would be abrogated by co-treatment with sirtuin 
inhibitors.  Accordingly, we examined the effect of nicotinamide, a sirtuin inhibitor [13], on 
neuroprotective actions of resveratrol and quercetin.  As shown in Fig. 3, protective effects 
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of resveratrol and quercetin at 100 μM against MPPP+-induced loss of dopaminergic neurons 
and whole tissue injury were not significantly affected by concurrent application of 0.3 and 3 
mM nicotinamide.  Sirtinol (100 μM), another sirtuin inhibitor, also showed no effect on the 
protective action of resveratrol (data not shown).  Nicotinamide and sirtinol did not affect 
MPP+ cytotoxicity by themselves.  These results suggest that sirtuin-activating properties of 
resveratrol and quercetin play a negligible role in their neuroprotective effects against MPP+ 
cytotoxicity. 
 
 The primary action of MPP+ is inhibition of complex I of the mitochondrial respiratory 
chain.  Complex I inhibition leads to an increase in production of reactive oxygen species 
(ROS), which in turn mediate MPP+ cytotoxicity [3].  Considering that polyphenol 
compounds including resveratrol possess antioxidative properties [11,26], we assumed that 
the protective effect of resveratrol against MPP+ cytotoxicity was relevant to reduction of 
oxidative stress.  To test this possibility, we measured DCF fluorescence as an indicator of 
intracellular ROS levels.  When loaded with DCFH-DA, slices treated with 20 μM MPP+ for 
48 h showed a clear increase in fluorescence of DCF, an oxidized product of DCFH.  
Concurrent application of resveratrol (30-100 μM) markedly attenuated MPP+-induced 
increase in DCF fluorescence (Fig. 4A).  We also measured the content of glutathione, a 
major endogenous antioxidant, in slice cultures.  Treatment of midbrain slice cultures with 
20 μM MPP+ for 48 h resulted in a marked decrease in tissue glutathione content, which was 
prevented by resveratrol (Fig. 4B). 
 
 To further verify that attenuation of oxidative stress is a key factor for neuroprotection by 
resveratrol, we performed immunohistochemistry for 8-hydroxyguanine.  8-Hydroxyguanine 
is a representative marker of cellular oxidative damage that reflects oxidative modification in 
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nuclear and mitochondrial DNA [23].  Many cells within midbrain slices treated with 20 μM 
MPP+ for 12 h exhibited increased immunoreactivity for 8-hydroxyguanine, as compared to 
those in slices without drug treatment.  Co-administration of 100 μM resveratrol with MPP+ 
prevented the increase in 8-hydroxyguanine-immunopositive signals (Fig. 4C-E). 
 
3.3. Resveratrol protects dopaminergic neurons from insults induced by DNA damage 
 
 Having shown that the protective effect of resveratrol against MPP+ cytotoxicity may be 
attributable to antioxidative properties, we set out to determine whether sirtuin-activating 
properties of resveratrol have a chance to play a role in dopaminergic neuroprotection.  For 
this purpose, we utilized MNNG, a DNA alkylating agent.  DNA damage triggers activation 
of enzymes for DNA repair such as poly(ADP-ribose) polymerase-1 (PARP-1; EC number 
2.4.2.30), whose over-activation depletes cellular NAD [27], possibly leading to suppression 
of NAD-dependent cellular processes including sirtuin activity [13].  Treatment of midbrain 
slice cultures with 1 mM MNNG for 72 h induced a significant decrease in the number of 
dopaminergic neurons.  MNNG also caused an increase in PI uptake into slices, although the 
degree of the increase was smaller than that induced by other insults such as MPP+, sodium 
azide and thrombin.  Concurrent application of NAD (100-500 μM) with 1 mM MNNG 
inhibited MNNG-induced dopaminergic cell death (Fig. 5A) and whole tissue injury (Fig. 5B), 
suggesting that MNNG neurotoxicity is mediated by depletion of NAD.  MNNG 
cytotoxicity was also suppressed by resveratrol in a concentration-dependent manner (Fig. 5C, 
D).  As to dopaminergic neurons, the protective effect of resveratrol was marginal at 1 μM, 
and a significant effect was observed at 10 and 100 μM. 
 
 Several target proteins for deacetylating activity of sirtuins have been identified [13].  
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Here we focused on the acetylation levels of p53, a tumor suppressor protein implicated in 
regulation of cell death and survival [28].  Western blot analysis demonstrated that the level 
of acetylated p53 increased in response to MNNG treatment in midbrain slice cultures (Fig. 
5E).  Resveratrol (1-100 μM) concomitantly applied with 1 mM MNNG blocked the 
increase of acetylated p53 level, suggesting that resveratrol indeed activated sirtuins 
mediating deacetylation of p53. 
 
 Finally, we examined SIRT1 expression in our midbrain slice cultures, by double 
immunofluorescence for TH and SIRT1.  We found that many, though not all, TH-positive 
neurons displayed diffuse immunoreactivity for SIRT1 (Fig. 5F).  SIRT1 immunoreactivity 
was also present in cells other than TH-positive neurons. 
 
 
4. Discussion 
 
 In this study we evaluated neuroprotective potential of resveratrol on midbrain 
dopaminergic neurons receiving several types of insults.  We first examined cytotoxicity of 
MPP+, a representative dopaminergic neurotoxin.  MPP+ applied under the present 
experimental conditions caused a substantial decrease in surviving dopaminergic neurons, but 
also a prominent increase in PI uptake into slices indicative of non-specific tissue injury.  
Indeed, MPPP+ and other dopaminergic neurotoxins were shown to require additional NMDA 
receptor stimulation to induce selective loss of dopaminergic neurons in organotypic culture 
consisting of substantia nigra, striatum and cortex [29].  In any case, resveratrol as well as 
another polyphenol compound, quercetin, was able to attenuate MPP+ cytotoxicity.  These 
observations are in line with a recent report showing that quercetin suppresses MPP+ 
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cytotoxicity on dopaminergic neurons in dissociated primary culture [30]. 
 
 We also demonstrated that resveratrol prevented cytotoxic effects of sodium azide and 
thrombin, in the same range of concentrations as that required to prevent MPP+ cytotoxicity.  
Sodium azide inhibits the activity of complex IV of the mitochondrial respiratory chain [31].  
A serine protease thrombin activates microglia, and triggers dopaminergic neurodegeneration 
via induction of inducible NO synthase and increased NO production [8].  Mitochodrial 
dysfunction and inflammatory processes associated with glial activation are two major factors 
involved in PD pathogenesis [2,5].  The fact that resveratrol effectively prevented 
dopaminergic neurodegeneration induced by these different insults suggests that resveratrol 
and related compounds are potentially useful in retarding dopaminergic neurodegeneration in 
PD. 
 
 We conclude that sirtuin activation does not play a major role in the protective effect of 
resveratrol against MPP+ cytotoxicity, because sirtuin inhibitors such as nicotinamide and 
sirtinol did not counteract neuroprotection by resveratrol.  Instead, we propose that 
antioxidative actions are responsible for neuroprotection by resveratrol against MPP+.  
Inhibition of mitochondrial complex I by MPP+ results in increased production of ROS, which 
plays a pivotal role in MPP+-induced degeneration of dopaminergic neurons [3].  Resveratrol 
is well known to exert potent antioxidative actions, and has been reported to attenuate ROS 
accumulation induced by NO donors in hippocampal neurons [16] or by β-amyloid in PC12 
cells [32].  Besides its own antioxidative properties, resveratrol may suppress oxidative 
stress via induction of cellular defense mechanisms against ROS.  In PC12 cells, resveratrol 
activates a transcription factor Nrf2, resulting in upregulation of cellular antioxidative factors 
such as glutathione and heme oxygenase-1 (EC number 1.4.99.3) [33].  Overall, these 
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properties of resveratrol are consistent with our present findings that resveratrol prevented 
ROS accumulation, glutathione depletion and cellular oxidative damage in response to MPP+. 
 
 We did not explore detailed mechanisms of the effect of resveratrol against cytotoxicity of 
sodium azide and thrombin, but we assume potential involvement of antioxidative actions 
also in these cases.  Application of sodium azide has been shown to increase production of 
ROS in brain tissues [34].  Concerning thrombin, we previously showed that a peroxynitrite 
scavenger FeTPPS and an antioxidant N-acetylcysteine could prevent dopaminergic 
neurodegeneration induced by thrombin [8], which suggests that peroxynitrite produced from 
the reaction of NO with superoxide is responsible for neurotoxicity.  Therefore, antioxidative 
actions of resveratrol are likely to play an important role in dopaminergic neuroprotection 
against these insults.  However, further investigations are required to draw a definitive 
conclusion, and we do not exclude the possibility that other mechanisms are involved in the 
protective action.  For example, we found here that a high concentration (100 μM) of 
resveratrol partially suppressed nitrite accumulation in response to thrombin.  This might be 
accomplished by direct scavenging of NO by resveratrol, but may also be mediated by actions 
of resveratrol on microglia.  A recent study has demonstrated that resveratrol prevents 
β-amyloid neurotoxicity by suppressing microglial signaling [35]. 
 
 DNA damage may contribute to dopaminergic neurodegeneration in PD, since increases 
in DNA strand breaks and oxidized guanine nucleotides have been identified in the midbrain 
of PD patients [36,37].  We showed in the present study that a DNA alkylating agent MNNG 
induces loss of dopaminergic neurons in slice culture.  An important observation is that 
NAD as well as resveratrol reversed MNNG-induced dopaminergic neurodegeneration.  
PARP-1, a DNA repair enzyme, is shown to be activated after exposure of astrocyte culture to 
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MNNG, which results in depletion of cellular NAD and cell death [27].  It is likely that 
MNNG treatment depletes cellular NAD also in dopaminergic neurons, thereby 
downregulating the activity of NAD-dependent enzymes including sirtuins. 
 
 p53 is one of the important substrates of sirtuins in relation to cell death regulation.  
Lysine residues at the C-terminal region of p53 are acetylated in response to DNA damage, 
which leads to stabilization of p53 protein, recruitment of co-activators, and induction of 
apoptotic cell death [38].  Sirtuins inhibit p53-dependent apoptosis via deacetylation of p53 
[28,39].  We indeed found here that increase in the levels of acetylated p53 was suppressed 
by resveratrol.  These results lend further support for the idea that sirtuin activation is 
responsible for the neuroprotective action of resveratrol against DNA damage.  Although we 
do not have conclusive evidence for direct involvement of p53 activation in MNNG-induced 
dopaminergic neurodegeneration, several studies implicate p53 as a mediator of dopaminergic 
cell death induced by other stimuli [40,41].  Yet, other deacetylation targets of sirtuins, such 
as NF-κB [35,42] and a Bax-associated protein Ku70 [43] might also play an important role 
in neurodegeneration induced by DNA damage and neuroprotection afforded by resveratrol.  
These possibilities warrant further investigation.  In this context, nuclear localization of 
NF-κB in midbrain neurons is found in PD patients [44], and sirtuin-dependent deacetylation 
results in downregulation of NF-κB in several cellular systems [11]. 
 
 Concentrations of resveratrol required to show neuroprotective actions were in a range of 
10 - 100 μM.  Other studies on primary neuronal cultures demonstrated effects of resveratrol 
at a similar concentration range (5 - 50 μM) [16,17,35].  On the other hand, peak serum 
concentrations of total resveratrol (including sulfated or glucuronide metabolites as well as 
unmodified resveratrol) are estimated to be ~180 nM at a dose equivalent to two glasses of 
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red wine [11].  Therefore, dosage of resveratrol obtained from dietary sources alone may not 
be large enough to exhibit neuroprotective actions.  An important point to be considered is 
that in vitro experiments generally employ high concentrations of neurotoxins to induce 
neuronal death within a few days.  Neuronal death in neurodegenerative disorders, which 
occurs gradually over many years under continuous presence of low levels of toxic insults, 
might be prevented by much lower concentrations of resveratrol than those used in the present 
study in vitro.  Moreover, resveratrol given as a medicine rather than as a dietary component 
may achieve sufficient plasma and brain levels to exert neuroprotective actions.  A 
pharmacologically relevant dose (100 mg/kg body weight) in rodents has been reported to 
give peak plasma concentrations of ~9 μM for unmodified resveratrol and ~680 μM for total 
resveratrol [11]. 
 
 In conclusion, resveratrol protects midbrain dopaminergic neurons against several 
different types of insults related to PD pathogenesis.  Different cellular and molecular 
mechanisms, such as antioxidative actions and regulation of sirtuin-dependent gene 
transcription, may be involved in the protective actions of resveratrol under different 
conditions.  Resveratrol may represent a novel seed for neuroprotective drugs aimed at 
prevention of PD. 
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Figure Legends 
 
Fig. 1.  Resveratrol and quercetin prevent MPP+-induced dopaminergic cell death and whole 
tissue injury.  (A-C) Representive photomicrographs showing TH immunohistochemistry of 
a slice cultured under control conditions (A), a slice treated with 30 μM MPP+ for 48 h (B) 
and a slice treated with 30 μM MPP+ plus 100 μM resveratrol (resv.) for 48 h (C).  Scale bar, 
50 μm.  (D-G) Effects of resveratrol and quercetin on MPP+-induced dopaminergic cell 
death (D and F) and PI uptake (E and G).  Resveratrol and quercetin at indicated 
concentrations were applied concomitantly with 30 μM MPP+ for 48 h.  Number of slices 
examined for each condition is 5-18.  *** p < 0.001 vs. control (Cont.); # p < 0.05, ## p < 
0.01, ### p < 0.001 vs. MPP+ alone. 
 
Fig. 2.  Resveratrol prevents dopaminergic cell death and whole tissue injury induced by 
sodium azide (NaN3) and thrombin.  (A and B) Effect of resveratrol on NaN3-induced 
dopaminergic cell death (A) and PI uptake (B).  Resveratrol at indicated concentrations was 
applied concomitantly with 200 μM NaN3 for 24 h.  (C-E) Effect of resveratrol on 
thrombin-induced dopaminergic cell death (C), PI uptake (D) and nitrite increase (E).  
Resveratrol at indicated concentrations was applied concomitantly with 300 U/ml thrombin 
for 72 h.  Number of slices examined for each condition in A-D is 14-32.  The number of 
culture wells examined for nitrite determination (E) are indicated in parentheses.  *** p < 
0.001 vs. control (Cont.); ## p < 0.01, ### p < 0.001 vs. NaN3 or thrombin alone. 
 
Fig. 3.  Sirtuins are not involved in the protective effects of resveratrol and quercetin against 
MPP+ cytotoxicity.  Effects of nicotinamide (0.3 and 3 mM) on the protective effects of 100 
μM resveratrol or quercetin against dopaminergic cell death (A) and PI uptake (B) induced by 
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30 μM MPP+ are shown.  All drugs were concomitantly applied to slice cultures for 48 h.  
Number of slices examined for each condition is 6-30.  *** p < 0.001 vs. control (Cont.); 
### p < 0.001 vs. MPP+ alone. 
 
Fig. 4.  Antioxidative properties are involved in the protective effect of resveratrol against 
MPP+ cytotoxicity.  (A and B) Effects of resveratrol on MPP+-induced increase in DCF 
fluorescence (A) and decrease in cellular glutathione (B) are shown.  Resveratrol at indicated 
concentrations was applied concomitantly with 20 μM MPP+ for 48 h.  Number of slices 
examined for each condition in A is 13-16.  Number of culture wells examined in B is 4 for 
each condition.  The mean value of glutathione content in control cultures was 36.1 nmol/mg 
protein.  *** p < 0.001 vs. control (Cont.); ## p < 0.01, ### p < 0.001 vs. MPP+ alone.  
(C-E) Photomicrographs showing 8-hydroxyguanine immunoreactivity of a slice cultured 
under control conditions (C), a slice treated with 20 μM MPP+ for 12 h (D) and a slice treated 
with 20 μM MPP+ plus 100 μM resveratrol (resv.) for 12 h (E).  Scale bar, 50 μm. 
 
Fig. 5.  Effects of NAD and resveratrol on MNNG cytotoxicity.  (A and B) NAD inhibits 
MNNG-induced dopaminergic cell death (A) and PI uptake (B).  NAD at indicated 
concentrations was applied concomitantly with 1 mM MNNG for 72 h.  (C and D) 
Resveratrol inhibits MNNG-induced dopaminergic cell death (C) and PI uptake (D).  
Resveratrol at indicated concentrations was applied concomitantly with 1 mM MNNG for 72 
h.  Number of slices examined for each condition is 12-39.  *** p < 0.001 vs. control 
(Cont.); # p < 0.05, ## p < 0.01, ### p < 0.001 vs. MNNG alone.  (E) Western blot analysis 
of acetylated p53 (ac-p53) after 72 h treatment of slice cultures with MNNG and/or 
resveratrol at indicated concentrations.  A representative blot of ac-p53 from two 
independent sets of experiments is shown with that of β-actin, a loading control.  (F) 
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Representative images of double immunofluorescence for TH (red) and SIRT1 (green) in 
midbrain slice cultures.  Arrowheads indicate dopaminergic neurons showing expression of 
SIRT1.  Scale bar, 50 μm. 
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